세계의 보행동결 치료 시장 규모 : 제품 유형별, 용도별, 지역별, 범위 및 예측

Freezing Of Gait Treatment Market Size And Forecast

Freezing Of Gait Treatment Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. The growing geriatric population worldwide is the biggest driver of the Freezing Of Gait Treatment Market. The Global Freezing Of Gait Treatment Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Freezing Of Gait Treatment Market Definition

Freezing of gait (FOG) is frequently regarded as one of the dopamine-resistant motor symptoms of Parkinsonism. Parkinson's disease is the second most prevalent neurodegenerative disorder, impacting about 1% of adults over 60 years of age. In persons above the age of 85, the incidence rises from 3% to 5%. Bradykinesia, resting tremor, rigidity, and lack of postural reflexes are the most common symptoms. As the disease progresses, most people with PD lose their postural reflexes, leading to walking difficulties and balance problems.

Stooped posture, freezing of gait (FOG) festination, shuffling steps, and falling are all common PD gait disorders. FOG, defined as an onset of inability to start effective steps without a known cause, is most particularly experienced during step initiation and turning, especially facing obstacles, doorways, stress, and distraction. Treatment with levodopa (L-dopa) or entacapone has been shown to improve Off-related FOG in recent studies. L-dopa has been shown to reduce the duration and frequency of FOG episodes. On-related FOGs are uncommon and difficult to diagnose. FOGs, like many other symptoms, are only resistant to treatment at the most advanced stages of the disease.

To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can considerably improve the symptoms of movement. High-dose levodopa can delay and reduce the occurrence of FOG when compared to placebo or low-dose levodopa. Levodopa can significantly decrease the number of episodes of akinesia and FOG. Levodopa can also reduce the frequency and duration of 'off'-related FOG. Deep brain stimulation (DBS) has been shown to improve FOG and reduce falls in FOG.

Global Freezing Of Gait Treatment Market Overview

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. Freezing of gait is a common symptom of Parkinson's syndrome and several other forms of parkinsonism. Freezing is a major burden for both patients and families since it often leads to falls, injuries from falls, and a loss of independence. Treatment of gait freezing is difficult due to a variety of factors, including its paroxysmal and changeable nature; comprehensive pathophysiology encompassing an interplay among motor (disturbed stepping mechanisms) and non-motor (cognitive decline, anxiety); and a complex (and likely heterogeneous) fundamental neural substrate, which includes multiple failing neural connections. As the disease is correlated with Parkinson's disease, the market is expected to grow healthy.

The growing geriatric population worldwide is the biggest driver of the market. According to a study, around 60,000 Americans are diagnosed with Parkinson's disease every year, therefore the market in North America has a lot of potential. Furthermore, it has been discovered that men are more vulnerable to developing such diseases than women. The rise in the geriatric population is also benefitting the Freezing Of Gait Treatment Market, since older people are more likely to become ill and suffer a variety of chronic or fatal diseases, as well as disorders that cause them pain throughout their life, such as spinal or joint pain. However, some patients develop side effects after taking medications related to the freezing of gait which might restrain the Freezing Of Gait Treatment Market growth.

Global Freezing Of Gait Treatment Market: Segmentation Analysis

The Global Freezing Of Gait Treatment Market is segmented on the basis of Product Type, Application, And Geography.

Freezing Of Gait Treatment Market, By Product Type

• Carbidopa/Levodopa
• Deep Brain Stimulation
• Wearable and Walking Aid Devices

Based on Product Type, The market is segmented into Carbidopa/Levodopa, Deep Brain Stimulation, and Wearable and Walking Aid Devices. Carbidopa/Levodopa segment is expected to grow at a significant rate during forecasted years. To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can significantly decrease the number of episodes of akinesia and FOG.

Freezing Of Gait Treatment Market, By Application

• Hospitals
• Clinics
• Others

Based on Application, The market is segmented into Hospitals, Clinics, and Others. The Hospitals segment is expected to grow at a significant rate during the forecasted years. This is owing to, symptomatic and neuroprotective therapies being preferred in Hospitals, according to FDA and other research studies.

Freezing Of Gait Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Freezing Of Gait Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Owing to the increased frequency of Parkinson's disease in North America especially the United States generated the highest revenue share in the Freezing Of Gait Treatment Market. Rising awareness of new medications and therapies, FDA approvals for new drugs, and an expansion in PD care services, as well as an improved reimbursement structure, will fuel demand in the near future.

Key Players

• The "Global Freezing Of Gait Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM, INC.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In November 2020: MedEXO Robotics is a Hong Kong-based robotics technology company that recently launched the ExoBeam walking device to help people with Parkinson's disease and other movement disorders. For continuous monitoring, the ExoBeam system consists of a small laser projector that can be attached to the wearer's pants, belt, or cane.
• In January 2018: GYENNO, a Chinese firm that develops technologies to help people with Parkinson's disease and other movement disorders, was showing off its Gait Aid Equipment package at the recent CES 2018 conference in Las Vegas.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL FREEZING OF GAIT TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL FREEZING OF GAIT TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Carbidopa/Levodopa
• 5.3 Deep Brain Stimulation
• 5.4 Wearable and Walking Aid Devices

6 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Others

7 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL FREEZING OF GAIT TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Acorda Therapeutics
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Teva Pharmaceuticals
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 GYENNO
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 MedEXO Robotics
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 APDM, INC
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research